IL33 and asthma: In a novel mechanistic study using samples from patients with uncontrolled asthma in the randomised, double-blind, placebo-controlled phase 2 UPSTREAM trial, tezepelumab decreased production of IL-33 in bronchoalveolar lavage at 12 weeks [55].